Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors

By |2020-02-12T00:41:19+05:30February 12th, 2020|

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that [...]

Zumutor Biologics raises $ 4 million in Series A2 funding

By |2019-11-29T15:33:04+05:30November 29th, 2019|

Zumutor Biologics, an Immuno-Oncology company developing novel mABs to drive transformational changes in the treatment of cancer raises 4Mil$ in series A2 funding taking its total raise to 20Mil$. The round includes funding by new investor Bharat Innovation Fund (BIF) with participation from its existing investor, Accel Partners. Zumutor’s growth strategy is focused on [...]

Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on “ Human Antibody Library Development for therapeutic monoclonal antibody products” at INNO 2018

By |2018-12-04T11:30:49+05:30December 4th, 2018|

Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on “ Human Antibody Library Development for therapeutic monoclonal antibody products” at INNO 2018, a two-day Antibody Symposium held on Monday, 3rd  December 2018, in Bengaluru, India. The symposium was designed  to expand the understanding of scientific advancements in antibody conjugates. Participants  included global [...]